Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease

The use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) has changed the clinical practice of dyslipidemia and their effects in cardiovascular events. Nowadays two active principles have been commercialized (evolocumab and alircumab) with indication in patients with low-density l...

Full description

Bibliographic Details

Published in:	Nefrología (English Edition)
Main Authors:	Borja Quiroga, Patricia Muñoz Ramos, Vicente Álvarez Chiva
Format:	Article
Language:	English
Published:	Elsevier 2020-09-01
Subjects:	Dislipemia Enfermedad renal crónica Eventos cardiovasculares iPCSK9
Online Access:	http://www.sciencedirect.com/science/article/pii/S2013251420301279